- $11.25bn
- $14.14bn
- $8.28bn
- 95
- 81
- 24
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.84 | ||
| PEG Ratio (f) | 0.57 | ||
| EPS Growth (f) | 20.92% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.18 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 10.06 | ||
| Price to Sales | 1.36 | ||
| EV to EBITDA | 8.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.8% | ||
| Return on Equity | 8.44% | ||
| Operating Margin | 13.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,797.29 | 5,480.83 | 7,741.39 | 8,120.18 | 8,281.68 | 8,263.36 | 8,663.35 | 24.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -5.07 | -24.82 | +40.4 | +22.75 | +28.37 | +25.99 | +11.48 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Directors
- Ciaran Murray NEC (58)
- Stephen Cutler CEO (60)
- Brendan Brennan CFO (42)
- Diarmaid Cunningham EVP (46)
- Ronan Murphy LED (63)
- Hugh Brady IND (61)
- John Climax IND (68)
- Joan Garahy IND (58)
- William Hall IND (71)
- Eugene McCague IND (62)
- Julie O'Neill IND (55)
- Mary Pendergast IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 31st, 1989
- Public Since
- May 15th, 1998
- No. of Employees
- 41,900
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 80,756,860
- Address
- South County Business Park, DUBLIN, 00000
- Web
- https://www.iconplc.com/
- Phone
- +353 12912000
- Auditors
- KPMG
Latest News for ICLR
Upcoming Events for ICLR
Q1 2025 ICON PLC Earnings Release
Q1 2025 ICON PLC Earnings Call
ICON PLC Annual Shareholders Meeting
Q2 2025 ICON PLC Earnings Release
Similar to ICLR
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 21:12 UTC, shares in Icon are trading at $139.32. This share price information is delayed by 15 minutes.
Shares in Icon last closed at $139.32 and the price had moved by -52.29% over the past 365 days. In terms of relative price strength the Icon share price has underperformed the S&P500 Index by -55.14% over the past year.
The overall consensus recommendation for Icon is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIcon does not currently pay a dividend.
Icon does not currently pay a dividend.
Icon does not currently pay a dividend.
To buy shares in Icon you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $139.32, shares in Icon had a market capitalisation of $11.25bn.
Here are the trading details for Icon:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ICLR
Based on an overall assessment of its quality, value and momentum Icon is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Icon is $213.13. That is 52.98% above the last closing price of $139.32.
Analysts covering Icon currently have a consensus Earnings Per Share (EPS) forecast of $13.69 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Icon. Over the past six months, its share price has underperformed the S&P500 Index by -48.14%.
As of the last closing price of $139.32, shares in Icon were trading -42.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Icon PE ratio based on its reported earnings over the past 12 months is 9.84. The shares last closed at $139.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Icon's management team is headed by:
- Ciaran Murray - NEC
- Stephen Cutler - CEO
- Brendan Brennan - CFO
- Diarmaid Cunningham - EVP
- Ronan Murphy - LED
- Hugh Brady - IND
- John Climax - IND
- Joan Garahy - IND
- William Hall - IND
- Eugene McCague - IND
- Julie O'Neill - IND
- Mary Pendergast - IND